Q-omics provides the consensus-scored SIM2 profile across patient tissues and cancer cell-line models. SIM2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SIM2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, SIM2 RNA expression shows 19,121 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where SIM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIM2 survival associations across molecular data types. SIM2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIM2 RNA expression–survival associations across cancer types. High SIM2 expression shows unfavorable associations in KIRC, ACC, BRCA, LGG, MESO and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SIM2 RNA expression.
This table summarizes SIM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SIM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIM2 shows lower tumor expression in KIRC, KIRP, KICH and HNSC and higher tumor expression in COAD and BLCA. The KIRC box plot shows higher SIM2 RNA expression in normal versus tumor tissue (log2 FC = −2.987, t-test p < 0.001).
This table shows molecular features associated with SIM2 in patient tissues and cancer cell lines. In patient samples, SIM2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SIM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
